USFDA successfully completes inspection at Indoco's API manufacturing facility at Patalganga with zero observations

Indoco Remedies Limited announced today that the United States Food and Drug Administration (USFDA) successfully completed inspection of its Active Pharmaceutical Ingredients (API) manufacturing facility at Patalganga, Navi Mumbai. The inspection concluded with zero form 483 observations, reflecting the company's commitment to the highest standards of quality, regulatory compliance and operational excellence.

"This successful USFDA inspection is a testament to the strong quality culture and compliance in every process and every product. We remain committed to strengthening our systems to deliver safe and efficacious medicines across the globe," said Ms. Aditi Panandikar, Managing Director, Indoco Remedies Limited.

Shares of Indoco Remedies Limited was last trading in BSE at Rs. 300.95 as compared to the previous close of Rs. 302.00. The total number of shares traded during the day was 8486 in over 573 trades.

The stock hit an intraday high of Rs. 311.75 and intraday low of 298.80. The net turnover during the day was Rs. 2574693.00.

Source : Equity Bulls

Keywords

IndocoRemedies INE873D01024 Pharmaceuticals USFDA Inspection API ManufacturingFacility Patalganga NaviMumbai ZeroObservations